Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Poseida Therapeutics (NASDAQ: PSTX) Enters into Strategic Collaboration Agreement with Roche to Develop Next-Gen Allogeneic CAR-T Cell Therapies

Poseida Therapeutics, Inc. (NASDAQ: PSTX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of next-generation cell therapies using its proprietary genetic engineering platform. Shares of the biopharma company are soaring 73% through afternoon trading on Wednesday, August 3, 2022. Over the past three months, Poseida Therapeutics has seen average daily volume of 232,610 shares. However, volume of 48.42 million shares or dollar volume of around $201.91 million, has already exchanged hands through afternoon trading.

Shares of Poseida Therapeutics are surging after the company announced it has entered into a global strategic collaboration and license agreement with Roche. The collaboration will be centered around developing allogeneic CAR-T therapies to treat hematologic malignancies. The two companies will focus on the research and development of exisint and “off-the-shelf” cell therapies to target multiple myeloma, B-cell lymphomas and other hematologic ailments.

Under the terms of the agreement, Poseida will grant Roche exclusive rights or the option to develop and commercialize allogeneic CAR-T programs within Poseida’s portfolio. Poseida Therapeutics has agreed to conduct Phase 1 clinical studies and manufacture clinical materials for its CAR-T portfolio before turning them over to Roche.

In exchange, Poseida Therapeutics will receive $110 million upfront and the option to receive an additional $110 million in near-term milestones over the next several years. In addition, the company could earn up to $6 billion from tiered net sales royalties, research, development, launch and more.

“We are thrilled that Roche has embraced the opportunity to partner with us and use Poseida’s unique allogeneic approach to develop CAR-T product candidates,” said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida. “Using our proprietary technologies and manufacturing process including our booster molecule, we have the potential to develop and manufacture a product with high levels of stem cell memory T cells, which are correlated with potent antitumor efficacy in the clinic, at a scale that can potentially reach more patients and enable broad commercial use.”

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Poseida Therapeutics (NASDAQ: PSTX) Enters into Strategic Collaboration Agreement with Roche to Develop Next-Gen Allogeneic CAR-T Cell Therapies appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.